QNTM Quantum Biopharma Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1771885 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q42025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q42024-12-31 | 2024Q32024-09-30 | 2024Q2*2024-06-30 | 2024Q1*2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $70,404 | $495,223 | $549,197 | $1.65M | $4.28M | $744,802 | $897,986 | $160,260 |
| SG&A expense | $1.37M | $3.04M | $3.31M | $1.33M | $1.93M | $3.25M | $2.31M | $1.92M |
| Operating income | -$2.37M | -$4.68M | -$4.85M | -$3.40M | -$6.24M | -$4.18M | -$3.46M | -$2.26M |
| Interest expense | -$72,637 | $91,570 | $116,962 | $22,168 | -$21,799 | $10,371 | $8,357 | $12,414 |
| Net income | — | $0 | $0 | $0 | — | -$3.83M | $0 | $0 |
| EBITDA | -$2.24M | -$4.53M | -$4.71M | -$3.27M | -$6.13M | -$4.06M | -$3.32M | -$2.14M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | — | — | — | — | — | 917,848 | 41.68M | — |
| Banking | ||||||||
| Net interest income | -$22,285 | $100,420 | $90,733 | $67,216 | $132,075 | $163,868 | $104,424 | $172,524 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.91M | $445,944 | $1.50M | $3.52M | $6.00M | $3.12M | $3.31M | $1.33M |
| Short-term investments | $459,080 | $636,761 | $30,786 | $20,868 | $1.20M | $3.49M | $21,918 | — |
| Receivables | — | — | — | — | — | $70,478 | — | — |
| Inventory | $52,133 | $77,622 | $76,869 | $93,856 | $117,242 | — | — | — |
| Current assets | $6.48M | $9.34M | $10.34M | $9.93M | $12.05M | $13.84M | $10.02M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $67,029 | $69,485 | $72,034 | $74,397 | $76,894 | $64,909 | $64,873 | — |
| Intangibles | $4.51M | $4.62M | $4.73M | $4.83M | $4.93M | $5.04M | $5.15M | — |
| Total assets | $11.16M | $14.15M | $15.30M | $14.87M | $17.12M | $19.03M | $15.25M | — |
| Current liabilities | $6.06M | $6.65M | $13.25M | $10.34M | $6.68M | — | $5.04M | — |
| Total liabilities | $6.06M | $6.65M | $13.25M | $10.34M | $6.68M | $3.68M | $5.04M | — |
| Shareholders' equity | $6.92M | $8.65M | $3.76M | $5.73M | $11.48M | $16.29M | $10.96M | $11.51M |
| Cash flow statement | ||||||||
| Operating cash flow | -$305,598 | -$1.72M | -$1.95M | -$4.26M | -$835,762 | -$3.46M | -$606,482 | -$1.97M |
| Investing cash flow | $350,650 | $408,419 | -$1.36M | -$1.35M | $1.24M | -$3.46M | $738,222 | -$22,140 |
| Financing cash flow | $1.41M | $261,425 | $1.29M | $3.13M | $2.47M | $6.74M | $1.84M | $568,719 |
| Depreciation & amortization | $129,371 | $145,336 | $141,383 | $129,690 | $112,803 | $120,814 | $136,813 | $120,141 |
| Stock-based compensation | $808,452 | $996,194 | $849,584 | $291,272 | -$82,477 | $65,424 | $111,524 | $57,743 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.